3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
16
Pancreatic Neoplasms
9
Stomach Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Carcinoma, Renal Cell
6
Carcinoma, Hepatocellular
6
Urinary Bladder Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Neoplasms
5
Melanoma
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Merkel Cell
4
Turcot syndrome
3
Triple Negative Breast Neoplasms
3
Small Cell Lung Carcinoma
3
Head and Neck Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Transitional Cell
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Microsatellite Instability
2
Gastrointestinal Neoplasms
2
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Cancer Resectable
1
Mesothelioma, Malignant
1
Liver Diseases
1
Interventions
Gemcitabine
4
130-nm albumin-bound paclitaxel
2
sintilimab
1
nimotuzumab
1
avelumab
1
Taxes
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Hydroxychloroquine
1
Fluorouracil
1
Capecitabine
1
Antineoplastic Agents
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Cancer Resectable
×
avelumab
×
Gastrointestinal
×
Clear all
NCT03344172
2020-05-14
17-134
University of Pittsburgh
Phase 2
Terminated
32 enrolled
14 charts